The vaccination for the hepatitis B virus (HBV) has been traced as the source of Sudden Infant Death Syndrome (SIDS) on hundreds of occasions. There are probably many more. So what do you do if a hospital pediatrician threatens to take your newborn baby from you if you reject the HBV vaccination?
It is often administered just after birth and usually repeated three times over the next six months. Even if it were an effective vaccine, it would be useless unless the mother is infected with hepatitis B, which is purportedly transmitted through injections with shared drug paraphernalia and/or promiscuous sex. (more…)
This story began 12 years ago, when I received a phone call from a prospective Canadian patient asking my advice about treating hepatitis C virus (HCV). He had acquired both hepatitis B and C infections from blood products used to treat hemophilia approximately 34 years earlier. Together we evaluated many claims of cure; tried promising remedies; and checked serum viral load, liver enzymes, and level of liver fibrosis. (Initially his biopsy revealed a level 3 cirrhosis, and FibroScan score >20.) Follow-up fibrosis studies were measured with the FibroScan. Years later his liver is now in the range of normal fibrosis (FibroScan 4.7). Remarkably, his serum HCV level was unchanged, still at 1 to 10 million copies/ml. (more…)
A recent news story described a newborn being taken away from her mother shortly after birth because of the mother’s refusal to allow the child to be vaccinated with a Hepatitis B vaccine. In my law practice, I hear stories from time to time about newborns being vaccinated in the hospital after birth without the parents’ permission. Most of the time, these kind of problems are avoidable with a little legal information and some common sense preparation. (more…)
We sought to expose the possible effect of hepatitis C virus (HCV) infection on oxidative stress indicators, nutritional status, and erythropoietin (rHuEPO) requirements in maintenance hemodialysis (MHD) patients. A total of 111 MHD patients (69 males, 42 females; mean age 51.3 +/- 13.0 years; MHD duration 78.5 +/- 52.1 months) and 46 healthy controls were enrolled in the study. We excluded patients with hepatitis B infection or malignancy. Indicators for oxidative status were studied in plasma samples obtained at the beginning of a clinically stable MHD session. Measurements were performed for plasma superoxide dismutase, glutathione peroxidase (antioxidative agents), and malonyldialdehyde (MDA; oxidative agent) by spectrophotometric methods. All patients were analyzed for the presence of anti-HCV; positive patients were also evaluated for the presence of HCV RNA. MHD patients were divided into three groups according to HCV infection status: group I (anti-HCV-positive, HCV-RNA-negative; n = 22); group II (anti-HCV-positive, HCV-RNA-positive; n = 22), and group III (anti-HCV-negative; n = 67). According to the analyses, MHD patients showed higher plasma oxidative stress indicators and lower antioxidative indicator levels compared to controls (P < .0001). MHD patients also displayed lower albumin and higher C-reactive protein (CRP) levels compared to controls (P < .0001). Antioxidant levels were decreased significantly from group I to III (P < .0001). MDA levels significantly increased from group I to III (P < 0.01). HCV-RNA-positive patients showed lowest albumin and highest CRP levels and rHuEPO requirements. Although alanine transferase (ALT) levels were in the normal range, group II patients had significantly higher ALT levels than the other groups (P < .01). In conclusion, we observed negative effects of active HCV infection on oxidative stress and rHuEPO requirements. In contrast, we detected that clinically inactive HCV infection was associated with reduced oxidative stress and rHuEPO requirements compared with active HCV infection and HCV-negative patients.
PMID: 20620489 [PubMed – indexed for MEDLINE]
Tutal E, Sezer S, Ibis A, Bilgic A, Ozdemir N, Aldemir D, Haberal M.
Department of Nephrology, Baskent University Hospital, Ankara, Turkey. firstname.lastname@example.org